Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V3-Cervix
- Development stage
- Phase 2
- Lead developer
- Immunitor
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
V3-Cervix is an oral tableted biological preparation developed by Immunitor LLC for the treatment of cervical cancer. It is derived from hydrolyzed, inactivated blood and tumor tissues of patients with cervical cancer. When administered orally, it is designed to elicit a specific anti-tumor immune response and an anti-inflammatory effect. The drug is currently being evaluated in a Phase II clinical trial.
Beyond the preview
Go deeper on V3-Cervix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V3-Cervix.